Q3 2018 13F Holders as of 30 Sep 2018
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
20,161,887
-
Share change
-
-439,862
-
Total reported value
-
$88,500,210
-
Put/Call ratio
-
169%
-
Price per share
-
$4.39
-
Number of holders
-
63
-
Value change
-
-$2,841,826
-
Number of buys
-
18
-
Number of sells
-
33
Institutional Holders of AVADEL PHARMACEUTICALS - COM (AVDL) as of Q3 2018
As of 30 Sep 2018,
AVADEL PHARMACEUTICALS - COM (AVDL) was held by
63 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
20,161,887 shares.
The largest 10 holders included
BRANDES INVESTMENT PARTNERS, LP, Broadfin Capital, LLC, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), ACADIAN ASSET MANAGEMENT LLC, BROWN CAPITAL MANAGEMENT LLC, Tekla Capital Management LLC, MORGAN STANLEY, DEUTSCHE BANK AG\, RENAISSANCE TECHNOLOGIES LLC, and BlackRock Inc..
This page lists
63
institutional shareholders reporting positions in this security
for the Q3 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.